viernes, 18 de septiembre de 2009

Educating the Public About Removal of Essential-Use Designation for Epinephrine


The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) is holding a public workshop on September 25, 2009 in Rockville, MD to discuss strategies for educating the public about the phase-out of chlorofluorocarbon (CFC)-propelled over-the-counter (OTC) epinephrine inhalers from the US market. The one day workshop will solicit input from key stakeholders in the asthma community, the pharmaceutical industry, experts in health care communication, and the public about how best to alert patients and transition them to therapeutic alternatives.
For more information, please visit: Epinephrine

Educating the Public About Removal of Essential-Use Designation for Epinephrine

The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) is holding a public workshop on September 25, 2009 in Rockville, MD to discuss strategies for educating the public about the phase-out of chlorofluorocarbon (CFC)-propelled over-the-counter (OTC) epinephrine inhalers from the US market. The one day workshop will solicit input from key stakeholders in the asthma community, the pharmaceutical industry, experts in health care communication, and the public about how best to alert patients and transition them to therapeutic alternatives.

OTC epinephrine metered-dose inhalers are FDA-approved for the temporary relief of shortness of breath, tightness in the chest, and wheezing due to asthma. But the medicine in these inhalers is currently propelled by gases known as chlorofluorocarbons (CFCs). CFCs are harmful to the environment because they decrease the protective ozone layer above the Earth. In order to comply with an international agreement, the Montreal Protocol on Substances that Deplete the Ozone Layer, CFC-propelled epinephrine OTC inhalers cannot be made or sold in the United States after December 31, 2011.

Federal Register Notice

abrir aquí:
-
Educating the Public About Removal of Essential-Use Designation for Epinephrine

No hay comentarios:

Publicar un comentario